Real-world Evidence Study of XEN in Chinese Patients With Refractory Glaucoma
NCT ID: NCT04303897
Last Updated: 2024-04-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
59 participants
OBSERVATIONAL
2019-12-19
2022-03-03
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Satisfaction With XEN Gel Stent Versus Trabeculectomy for the Treatment of Glaucoma
NCT03852810
A Study to Evaluate Adverse Events and Change in Disease Activity With the XEN45 Glaucoma Treatment System Implantation In Adult Participants With Open-Angle Glaucoma in China
NCT05821855
XEN-45 Gel Stent Versus Trabeculectomy in Glaucoma: Gold-Standard Pathway Study (GPS)
NCT03654885
Longitudinal Study on Glaucoma Surgery Using XEN® Gel Stent
NCT03151577
XEN45 in the Treatment of Chinese Patients With Primary Open-angle Glaucoma
NCT05130554
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
XEN Glaucoma Stent
XEN Glaucoma Stent
Data are collected from patients who are implanted with XEN via the specific urgent medical needs for named patient use regulatory pathway in Hainan
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
XEN Glaucoma Stent
Data are collected from patients who are implanted with XEN via the specific urgent medical needs for named patient use regulatory pathway in Hainan
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Previous glaucoma shunt/valve in the target quadrant
* Presence of conjunctival scarring, prior conjunctival surgery or other conjunctival pathologies (eg, pterygium) in the target quadrant
* Active inflammation (eg, blepharitis, conjunctivitis, keratitis, uveitis)
* Active iris neovascularization or neovascularization of the iris within six months of the surgical date
* Anterior chamber intraocular lens
* Presence of intraocular silicone oil
* Vitreous present in the anterior chamber
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Allergan
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
ALLERGAN INC.
Role: STUDY_DIRECTOR
Allergan
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Boao Super Hospital /ID# 233669
Qionghai, Hainan, China
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
clinical study report synopsis
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1924-801-007
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.